The START Center for Cancer Research - Logo

Blog

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline

Blog /

Discover how XenoSTART’s clinic-to-bench pipeline delivers more clinically relevant PDX models, real-world patient data, and accelerated drug development. Patient-derived xenograft (PDX) models provide the most accurate way to mimic clinical tumor characteristics and behavior in preclinical studies. By directly transplanting tumor tissue from patients into immunodeficient hosts, resulting PDX models preserve the original human tumors’ […]

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline Read More »

Thomas' Patient Story

Together in the Fight Against Cancer: Thomas’ Story of Community and Care

Blog /

“I was thinking about this the other night, one of the things that changed was I stopped flossing, because I figured, what’s the point?” Thomas recalls, sitting in a treatment room at START Mountain Region, reflecting on how his perspective had changed after getting his cancer diagnosis. Thomas, who works full-time as a bartender in

Together in the Fight Against Cancer: Thomas’ Story of Community and Care Read More »

Malignant Hematology Blog Banner

Breaking Barriers in Blood Cancer Treatment: Insights on the Future of Malignant Hematology

Blog /

A recent START webinar titled Malignant Hematology: Advancing Treatment in Blood Cancers, provided an in-depth look into the current advancements and challenges in treating hematological malignancies. Moderated by Dr. Andrew Sochacki, Associate Director for Hematology and Clinical Research at START Midwest, the session brought together leading experts to discuss myeloid malignancies, lymphoid malignancies, plasma cell

Breaking Barriers in Blood Cancer Treatment: Insights on the Future of Malignant Hematology Read More »

Advancing ADC Development

Advancing ADC Development: Expert Panel Explores Current Landscape and Future Opportunities

Blog /

Antibody-drug conjugates (ADCs) are among the most promising innovations in cancer treatment today, combining the targeting precision of monoclonal antibodies with the potent killing power of cytotoxic drugs. In a recent webinar hosted by The START Center for Cancer Research (“START”), a distinguished panel of oncologists and researchers explored the science, challenges, and future directions

Advancing ADC Development: Expert Panel Explores Current Landscape and Future Opportunities Read More »

Dr. Moreno Wearables Blog

Wearable Technology in Early-Phase Cancer Trials: Advancing Objective Performance Measures

Blog /

The integration of wearable technology into early-phase cancer trials represents a pivotal moment in oncology research, offering the ability to transform how we assess and predict clinical outcomes for patients. Traditional methods such as the Karnofsky Performance Status (developed in 1948) and ECOG Performance Status (introduced in 1982) have been the gold standard for decades.

Wearable Technology in Early-Phase Cancer Trials: Advancing Objective Performance Measures Read More »

Why Adpative

Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research

Blog /

Randomized clinical trials (RCTs) began in the 1940s with streptomycin’s evaluation against tuberculosis. Since then, RCTs have been the foundation of clinical trial design, ensuring therapies reach patients safely. For decades, oncology trials followed a set pattern: drugs were tested in preclinical models, followed by dose escalation to assess safety, toxicity, and efficacy compared to

Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research Read More »

Capturing the Complexity

Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models

Blog /

Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models One of the most significant areas of advancement in oncology is the growing capacity to match patients with therapies tailored to their unique cancer. As more relevant biomarkers and druggable targets are identified, drug developers still face an evergreen challenge: narrowing down the most

Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models Read More »

ClinicalTrials

Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies

Blog /

Accelerating Targeted Cancer Therapy Trials: Perspectives from START  Key Highlights Significant increase in FDA-approved targeted cancer therapies over the past decade. Low prevalence of specific mutations and variable toxicities of targeted therapies are important challenges to consider when starting a trial. Selecting sites with expertise is crucial to timely completion of trials with accurate reporting. 

Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies Read More »

DrivingOncology

Driving Oncology Research Progress Through Access to Early-Phase Trials

Blog /

The START Center for Cancer Research represents a global team of leading investigators in medical oncology, driven by a commitment to improving clinical trial access for patients treated in community oncology centers. Emiliano Calvo, MD, PhD, and Victor Moreno, MD, PhD, serve as Directors of Clinical Research at START Madrid-CIOCC and START Madrid-FJD, respectively. As

Driving Oncology Research Progress Through Access to Early-Phase Trials Read More »

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Contact Us
Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

Who We Serve

Services

About

Resources

START Locations

Patients & Family

Find a Trial
The START Center for Cancer Research - Logo

© 2025 START Research. All rights reserved.

Facebook Linkedin X-twitter